{"name":"Leonard-Meron Biosciences, Inc.","slug":"leonard-meron-biosciences-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Mino-Lok","genericName":"Mino-Lok","slug":"mino-lok","indication":"Prevention of catheter-related bloodstream infections (CRBSIs) in patients with central venous catheters","status":"phase_3"}]}],"pipeline":[{"name":"Mino-Lok","genericName":"Mino-Lok","slug":"mino-lok","phase":"phase_3","mechanism":"Mino-Lok is a antimicrobial lock solution that prevents biofilm formation and reduces bacterial colonization on central venous catheters.","indications":["Prevention of catheter-related bloodstream infections (CRBSIs) in patients with central venous catheters"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNN2NJNnAwMk9fVzdxeVNKVDRMd0RzVHVvckwyQ3VwaTkzLU1IazJRUzhXWGlKdWp0dy1iNGZ2Nlk3R01NdUdHTnhoRFU3SUZWWUh0bFpraUpYQzRuLUwtSnVPczFXSWQ0V0doQ1QxQXdLVDRPTUR5ZVh3SzRMZldaMlNaRlFHUWJmQ2taag?oc=5","date":"2026-02-13","type":"pipeline","source":"Pharmaceutical Executive","summary":"Leonard Mazur: The Adventures of a Serial Entrepreneur - Pharmaceutical Executive","headline":"Leonard Mazur: The Adventures of a Serial Entrepreneur","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxOdlpXanUxN0c0V1M2elpXLVNvd3ctRC1Hbl9uT3FNMHUxM01ZNmVvTGIxV25FZjk1OVFtNHp5dWRQcm1EV3dLTnJORG83bWpnTFhHaGJUaG5IWmNvbEQ5OHRIRTJvd0RfaE1SV0c1R20zbVpUclBXX0pXVmlncU1TYlQyWUJ4aUhRTmk2VVcwd200d2VkRTZFZjNQM2pDRFVNRXA0ZmlldGpkZ0FlQWVhaU90V1B5NVNxSzhvNWpnYXZWNjhnbGd5UlVRTTQ4SFUtRDVsclQxTHQ3UGctMURTZXBsQ1RHYmlPUEc1Qzl0XzBDVHV4bW80STdXVmhGU3FLcmE0VWNPeFF4OWlzT1lkVDlvbjY0NEJ6dVUwRVN0QQ?oc=5","date":"2021-10-01","type":"pipeline","source":"PR Newswire","summary":"Temple University Renames College of Liberal Arts Main Campus Building in Honor of Citius Pharmaceuticals Executive Chairman Leonard Mazur - PR Newswire","headline":"Temple University Renames College of Liberal Arts Main Campus Building in Honor of Citius Pharmaceuticals Executive Chai","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPdzJ1M051NEEycjZnSk9rZ2U3cmtoQmpWcUtaNjBlYXRNc3VhNTJFU3lSUzlVZjdJSV83WkJtc1dqcloxNm9NdXpudV9yMW1vanM0Sk9pRzBybVZrbTcwLWoyQ2hHRzUxNGRnMzNvWkFCbjEtNnJPUEZyeG16blFDX3BpNWdBQnpCdF9GMmFfWVBWc0o5SERXV2dsQXAzczhtSGt5RllDUFR1aVQ4anJBdXF3?oc=5","date":"2021-09-30","type":"pipeline","source":"The Business Journals","summary":"Citius Pharmaceuticals executive chairman donates $5M to Temple University - The Business Journals","headline":"Citius Pharmaceuticals executive chairman donates $5M to Temple University","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}